Idenix Pharmaceuticals (IDIX) Slammed As Shares Slapped with a "Sell"
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Price: $24.50 --0%
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) are down 10 percent in pre-open trading Friday after Stifel Nicolaus downgraded the high-flyer from Hold to Sell.
The firm downplayed the recent M&A speculation on the name which has followed the takeovers of Inhibitex, Inc. (INHX) and Pharmasset in the Hep-C space.
Shares of IDIX have more than doubled since Jan 6 rumors they would be next.
Weakness in Idenix could spill over to Achillion Pharmaceuticals (Nasdaq: ACHN), another rumored takeover target in the Hep-C space.
The firm downplayed the recent M&A speculation on the name which has followed the takeovers of Inhibitex, Inc. (INHX) and Pharmasset in the Hep-C space.
Shares of IDIX have more than doubled since Jan 6 rumors they would be next.
Weakness in Idenix could spill over to Achillion Pharmaceuticals (Nasdaq: ACHN), another rumored takeover target in the Hep-C space.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Virtu Financial said to explore $3.5B sales of brokerage unit
Create E-mail Alert Related Categories
Downgrades, Momentum Movers, Rumors, Trader TalkRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
